Apricot Capital

Sieran Medical is a medical device company that provides precise and intelligent minimally invasive surgical treatment solutions for ophthalmology.

Simcere Pharmaceutical Group is a prominent manufacturer and distributor of pharmaceuticals based in Nanjing, China, founded in 1995. The company has transitioned from a distributor to a leading player in China's pharmaceutical market, operating five GMP-certified manufacturing facilities and maintaining a strong workforce of over 4,000 employees. Simcere's product portfolio encompasses a wide range of medications targeting various therapeutic areas, including oncology, nervous system diseases, autoimmune disorders, and infections. Notable products include recombinant human endostatin injection for lung cancer, edaravone for acute cerebral infarction, and various formulations of amoxicillin for infections. The company also develops treatments for conditions such as arthritis, diarrhea, and cardiovascular diseases. Simcere has established strategic partnerships with organizations like Bristol-Myers Squibb and Jiangsu Alphamab Biopharmaceuticals to enhance its research and development capabilities.

Zhonghe Gene is a biotechnology company specializing in the development of advanced DNA biosynthesis technology. Its core innovations include enzymatic DNA synthesis technology, a range of oligo biosynthesis instruments, and a desktop gene synthesizer capable of producing kilobase-level DNA sequences. By providing these cutting-edge tools, Zhonghe Gene aims to enhance capabilities in biological laboratories and facilitate significant advancements in life sciences research, particularly in the field of synthetic biology. Through its work, the company contributes to the ongoing evolution and industrial advancement of genetic research.

Sinovent, established in 2016, is a global biopharmaceutical company with headquarters in Suzhou, China, and offices in Beijing, China, and Boston, U.S.A. It specializes in developing advanced treatments for global healthcare challenges, with a focus on oncology, autoimmune diseases, and infectious diseases. Sinovent's portfolio comprises 12 products in various stages of development, leveraging its expertise in science, management, and finance to deliver innovative solutions to patients worldwide.

Yiteng Medical manufactures medical devices. The business's basic products are medical CT tubes and industrial CT microfocus X-ray tubes.

Arnatar Therapeutics is a biopharmaceutical company that specializes in the development of novel nucleic acid medications.

LinkZill is a high-tech company specializing in the development and supply of organic semiconductor materials and thin-film transistors (TFT) arrays. Its innovative products cater to various emerging industries, including biomedical electronics, healthcare, and intelligent sports, as well as novel printed display technologies. By focusing on organic materials, LinkZill aims to support advancements in these fields, leveraging its expertise to provide solutions that meet the demands of modern technology.

Axiata is a technological business that combines product creation, research, and sales of lab supplies. The company enables in vitro diagnostic reagent producers, pharmaceutical firms, and biological preparation businesses to build value by offering them effective services and products. The company continues to work in harmony with clients while providing goods that satisfy consumer demand. Customers can purchase products and OEM services from them.

Qihe Biotech is a manufacturer based in Zibo, China, specializing in the research and development, production, and export of edible fungi. The company focuses on creating high-quality edible fungus products and aims to serve diverse markets across various countries. In addition to its product offerings, Qihe Biotech provides technical guidance services to customers in different regions, enhancing their ability to meet local market demands. Through its commitment to innovation and quality, the company seeks to establish a strong presence in the global edible fungi industry.

Qihe Biotech develops novel genome editing technologies with an emphasis on making them autonomous and programmable.

PharmCube is a comprehensive big data service platform tailored for the pharmaceutical industry. The company focuses on establishing systematic drug data standards and conducts in-depth data mining to connect various aspects of drug research and development, clinical trials, registration, access, sales, and investment. By providing essential real-time data, PharmCube enables pharmaceutical companies to enhance their development planning and market positioning. Its services encompass data provision, media information, and consulting, making it a crucial resource for stakeholders in the pharmaceutical sector seeking to optimize their operations and decision-making processes.

Etern is developing small molecule drugs for protein liquid-liquid phase separation, using the LLPS platform for AI-enabled target discovery, high-throughput screening, and optimization. This could open new treatment strategies for major diseases.

GRIT Biotechnology, established in 2019 and based in Shanghai, China, specializes in the research and development of Tumor Infiltration Lymphocytes (TIL) immunotherapy for treating solid tumors. The company aims to enhance cancer therapies by focusing on this innovative approach.

Hepagene Therapeutics is a biopharmaceutical company focused on developing innovative treatments for liver diseases. The company is dedicated to researching and creating therapies for conditions such as non-alcoholic steatohepatitis (NASH), chronic Hepatitis B infection, and liver cancer. Hepagene Therapeutics aims to address the significant unmet medical needs in the field of hepatology, striving to improve patient outcomes through its targeted drug development efforts.

Forerunner Medical (Shanghai) Co., Ltd., established in 2009, specializes in the development and manufacturing of innovative medical devices aimed at minimally invasive treatments. The company focuses on creating low-temperature plasma radio-frequency generators and electrodes specifically designed for sports medicine and tumor treatment. By leveraging extensive domestic clinical data and advanced technology, Forerunner Medical aims to meet both domestic and global healthcare needs. The organization emphasizes the quality and safety of its products, ensuring high performance, aesthetic appeal, and user convenience. Its commitment to excellence is reflected in its state-of-the-art production equipment and professional expertise, which contribute to its competitive advantage in the medical device industry.

MediLink Therapeutics is a China-based developer of antibody-drug conjugates (ADC) focused on cancer therapy. The company advances next-generation ADCs and aims to address unmet medical needs in China, while pursuing global value through multicenter clinical trials and cross-border collaborations. Its R&D center is in Suzhou.

GensKey is a medical diagnostic service provider specializing in genetic testing for pathogen diagnosis. The company utilizes high-throughput sequencing technology combined with intelligent algorithm analysis to address challenges associated with traditional diagnostic methods, such as low detection rates, lengthy processes, and accuracy issues. By improving the timeliness and precision of pathogen diagnosis, GensKey enables patients suffering from severe infections to receive prompt and reliable diagnoses, thereby enhancing the potential for effective treatment and recovery.

Shenqi Medical specializes in the research and manufacturing of innovative medical devices, primarily targeting the Chinese market. The company offers a diverse product portfolio that includes solutions for cardiovascular issues, structural heart diseases, and both peripheral and neurovascular medical devices. Additionally, Shenqi Medical is dedicated to developing minimally invasive surgical products, which enhance the safety and reliability of cardiovascular surgeries. Through its focus on advanced medical technology, Shenqi Medical aims to improve patient outcomes and contribute to the evolving landscape of healthcare.

Jabrehoo focusing on clinical transformation and innovative research and development of related products in the field of assisted reproduction, genetics and eugenics, providing one-stop solutions for reproductive genetics for assisted reproduction couples, infertile patients, and people who are preparing for pregnancy, and promoting the localization of various detections.

Immvira, established in Shenzhen, China, in May 2015, is a biotechnology company focused on developing innovative immunotherapy solutions for cancer treatment. Founded by a team of renowned researchers, including Professors from prestigious institutions, Immvira specializes in biopharmaceutical technology centered on oncolytic viruses and vector-based methods. The company’s flagship product is a genetically engineered Oncolytic Herpes Simplex Virus, designed to target metastatic tumors and those that are difficult to reach through traditional injection methods. By leveraging its advanced biotechnology platform, Immvira aims to improve treatment outcomes for cancer patients, providing effective therapeutic options for challenging tumor types.

MicroPort CardioFlow Medtech focuses on developing and commercializing transcatheter and surgical solutions for valvular heart diseases. As a subsidiary of MicroPort Scientific Corporation, it concentrates on minimally invasive therapies, combining research, manufacturing, and technical support to bring valve treatment options to clinicians and patients. Its portfolio includes VitaFlow, VitaFlow Liberty, and Alwide Plus, along with various transcatheter, surgical valve products, and procedural accessories. The company derives most of its revenue from China, selling through appointed distributors, and pursues a global vision with emphasis on quality, reliability, and affordability. The mission is to save lives and improve quality of life by delivering comprehensive, evidence-based solutions for structural heart disease through ongoing innovation and collaboration.

Yachuang Pharmaceuticals is an innovative pharmaceutical research and development company focusing on liver diseases such as NASH and HBV. Founder Dr. Xu has worked in multinational pharmaceutical companies such as Johnson & Johnson, with over 20 years of successful innovation and management of innovative drugs. experience.

SinoMab Bioscience is a biopharmaceutical company focused on researching, developing, manufacturing, and commercializing monoclonal antibody-based therapeutics for immunological diseases. It develops therapeutic antibodies for life-threatening conditions, with emphasis on rheumatoid arthritis and related disorders such as systemic lupus erythematosus and Sjögren's syndrome, as well as other indications including non-Hodgkin's lymphoma. Its flagship antibody SM03 (Suciraslimab) is positioned as a first-in-class targeted therapy for rheumatoid arthritis and potentially for other immunological diseases.

Tavotek Biotherapeutics is a biopharmaceutical company dedicated to discovering, developing, and commercializing therapeutic medicines for patients with severe, underserved diseases. Led by experienced pharmaceutical executives, the company employs three distinct research and development platforms: TavoSelect, an innovative phage display library; TavoPrecise, a platform for engineering tissue-specific biologics; and TavoMIP, a multicyclic peptide platform. Tavotek's pipeline includes various product candidates targeting cancers, autoimmune conditions, and infectious diseases.

Jiuxin Medical is a medical company that provides pre-hospital first-aid products and solutions for cardiovascular fields. The company was founded by a group of like-minded people who have mastered the industry's leading expertise and operational experience. The company has been approved for dozens of invention patents, and the products developed have complete independent intellectual property rights.

Bellen Chemistry is a premier provider of a variety of heterocycles. Our activity is focused on the design and development of novel molecules,6361413375267061158256368.jpgintermediates for the Chemical and Pharmaceutical industries. Bellen Chemistryhas a strong R&D team with a talent pool of 200+ trained scientists. We have excellent track records, as we deliver unrivalled chemical innovation to our customers worldwide.

Ambrx, Inc. is a clinical-stage biopharmaceutical company based in La Jolla, California, specializing in the development of engineered precision biologics through an expanded genetic code technology platform. This innovative approach enables the incorporation of synthetic amino acids into proteins, facilitating the creation of next-generation therapeutics. Ambrx focuses on various product candidates, including antibody drug conjugates (ADCs), bispecific antibodies, targeted immuno-oncology treatments, and long-acting therapeutic peptides aimed at addressing metabolic and cardiovascular diseases. The company has a robust development pipeline featuring multiple clinical and preclinical programs, with its lead candidate ARX788 among them. Ambrx also collaborates with other organizations, such as MabSpace Biosciences and BeiGene, to enhance its research and development efforts in oncology and other therapeutic areas. Founded in 2003, Ambrx is committed to advancing the efficacy and safety of new biologic therapies for patients.